Deferred Tax Assets, Valuation Allowance of Nurix Therapeutics, Inc. from 30 Nov 2019 to 30 Nov 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Nurix Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 30 Nov 2019 to 30 Nov 2024.
  • Nurix Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 30 Nov 2024 was $227,050,000, a 17% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Nurix Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $227,050,000 +$33,333,000 +17% 30 Nov 2024 10-K 28 Jan 2025 2024 FY
Q4 2023 $193,717,000 +$55,355,000 +40% 30 Nov 2023 10-K 28 Jan 2025 2024 FY
Q4 2022 $138,362,000 +$54,845,000 +66% 30 Nov 2022 10-K 15 Feb 2024 2023 FY
Q4 2021 $83,517,000 +$36,109,000 +76% 30 Nov 2021 10-K 09 Feb 2023 2022 FY
Q4 2020 $47,408,000 +$7,645,000 +19% 30 Nov 2020 10-K 28 Jan 2022 2021 FY
Q4 2019 $39,763,000 30 Nov 2019 10-K 16 Feb 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.